CROS and Quality of Life of Elderly Cochlear Implant Recipients and Their Care Givers
Launched by UNIVERSITY OF UTAH · Mar 10, 2021
Trial Information
Current as of May 01, 2025
Completed
Keywords
ClinConnect Summary
Cochlear Implants (CI) are now a well-accepted treatment for individuals with severe to profound hearing impairment. Compared to using one CI, bilateral CIs are known to provide access to some of the benefits of binaural hearing like improved speech understanding in noise (primarily due to headshadow), improved localization, reduced stress and fatigue, and improved quality of life (e.g., Dunn et al. 2012, Litovsky et al. 2012, Härkönen et al. 2016, Reeder et al. 2014, Agrawal 2008). However, a number of CI recipients are unable to or choose not to be implanted bilaterally for many reasons. ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Unilateral recipients of Advanced Bionics CII/90K/Ultra implants
- • Ages 18 years and above
- • At least 6 months of CI use experience
- • Current users of a Naida CI Q70 or Q90 processor
- • Do not currently use a Naida Link CROS device
- • Limited usable/aidable hearing in the contralateral ear
- • Fluent in spoken English
- • Willingness to use the CROS device regularly for the study duration
- • Willingness to follow-up on a biweekly/monthly basis
- Exclusion Criteria:
- • \< 6 months of CI use experience
- • \< 30% sentence recognition scores in quiet with unilateral CI
- • Inability to participate in speech testing
- • Inability to follow and complete questionnaires
- • Inability to designate an FC
- • not a unilateral recipient of Advanced Bionics CII/90K/Ultra implants
- Frequent communication partner (FCP) participants' inclusion criteria:
- • Ages 18 years and above
- • Fluent in spoken English
- • Willingness to participate in the study
- • Spends at least two hours of in-person interactions with the recipient of Advanced Bionics CII/90K/Ultra implants every week.
- FCP's Exclusion criteria:
- • Under the age of 18 years
- • Not fluent in spoken English
- • Spends less than two hours of in-person interactions with the recipient of Advanced Bionics CII/90K/Ultra implants per week
About University Of Utah
The University of Utah is a prestigious research institution known for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure that supports a wide range of biomedical research initiatives, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies. By fostering collaboration among researchers, clinicians, and community partners, the University of Utah aims to translate scientific discoveries into effective therapies and interventions, ultimately enhancing health outcomes and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Richard Gurgel, MD
Principal Investigator
University of Utah
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials